TRAILshort is an alternatively spliced form of the TRAIL gene. The best-known TRAIL proteins participate in programmed cell death, a process through which immune cells eliminate infected or malignant cells. TRAILshort, however, has a distinct structure and biological behavior. Mayo Clinic scientists first identified it while investigating HIV nearly 15 years ago, and later found that cancer cells can also produce it. Until now, its precise effect on immune signaling had remained unclear. The new research shows that TRAILshort does more than interfere with cell death: it directly disrupts the signaling machinery that allows T cells to recognize and respond to danger.

T cells rely on the T-cell receptor, or TCR, to detect molecular fragments displayed by infected or abnormal cells. Once the receptor is engaged, a chain of phosphorylation events activates signaling proteins that reorganize the cell, promote cytokine production and enable the T cell to kill its target. The Mayo Clinic team found that TRAILshort interrupts this process by activating SHP-1, a protein tyrosine phosphatase. SHP-1 removes phosphate groups from key signaling molecules, effectively applying a biochemical brake before the T cell can complete its activation program.

The result is a form of immune tolerance that benefits diseased cells. When TRAILshort levels are elevated, T cells may encounter cancer cells or infected cells but fail to generate a sufficiently strong response. This mechanism was detected in melanoma, lung, breast, pancreatic and ovarian cancers, as well as Hodgkin lymphoma. Elevated TRAILshort was also associated with infectious diseases including HIV, COVID-19, tuberculosis and hepatitis C. The broad distribution of the protein suggests that it may represent a shared pathway of immune dysfunction rather than a mechanism restricted to a single tumor type or pathogen.

The researchers used highly specific antibodies and engineered preclinical models to examine the protein’s activity. When TRAILshort was blocked, T cells regained signaling capacity and showed improved functional responses against diseased cells. These findings are significant because immune failure in cancer and chronic infection is often attributed to a combination of suppressive signals within the tissue environment. TRAILshort appears to be one of those signals, acting at an early stage of T-cell receptor signaling and potentially preventing immune cells from entering a fully active state.

The study also examined chimeric antigen receptor T-cell therapy, or CAR-T therapy. In this treatment, a patient’s T cells are genetically modified to express synthetic receptors that recognize specific cancer-associated molecules. Although CAR-T therapy can produce durable remissions in some blood cancers, its effectiveness can be limited when tumor cells create an immunosuppressive environment. In preclinical experiments, TRAILshort reduced the ability of CAR-T cells to control tumors. Removing or blocking the protein restored CAR-T activity, indicating that TRAILshort may be an important barrier to the success of cellular immunotherapies.

A therapy directed against TRAILshort could therefore be used alongside CAR-T cells, immune checkpoint inhibitors or other treatments designed to activate antitumor immunity. The protein might also serve as a biomarker. Tumors with high TRAILshort expression could be more likely to resist immune-based treatments, while patients whose tumors show lower levels might respond differently. Before such applications can be considered in humans, researchers will need to determine how TRAILshort is produced, how it moves through the tumor microenvironment and whether blocking it causes excessive inflammation or autoimmune complications.

The mechanism may also be relevant to viral disease. Chronic infections such as HIV and hepatitis C can drive prolonged immune stimulation, followed by T-cell exhaustion and functional decline. During COVID-19 and tuberculosis, immune regulation can become similarly unbalanced, with inadequate pathogen control in some patients and damaging inflammation in others. Because TRAILshort appears in several of these conditions, researchers are investigating whether it contributes to a common pattern of immune suppression. If so, carefully timed TRAILshort inhibition could potentially strengthen antiviral or antimicrobial responses, although such an approach would require precise control to avoid worsening immunopathology.

The same biology could have an opposite therapeutic use in autoimmune disease and transplantation. In cancer and persistent infection, researchers may seek to reduce TRAILshort activity and release the brake on T cells. In lupus, Crohn’s disease or transplant rejection, increasing TRAILshort activity could theoretically dampen harmful immune responses without broadly suppressing the immune system. This two-directional strategy remains experimental, and additional studies are needed to establish whether the protein can be safely manipulated in patients. The discovery nevertheless provides a defined molecular target for regulating T-cell behavior across cancer, infection and immune-mediated disease.

Subject of Research: TRAILshort-mediated suppression of T-cell signaling in cancer, viral infection and immune-related diseases.

Article Title: TRAIL splice variant TRAILshort disrupts T cell receptor signaling and promotes immune tolerance in vivo

Web References: Mayo Clinic; Journal of Clinical Investigation: https://www.jci.org/articles/view/194449

References: Journal of Clinical Investigation, “TRAIL splice variant TRAILshort disrupts T cell receptor signaling and promotes immune tolerance in vivo,” published 3 August 2026.

Keywords: TRAILshort, T cells, T-cell receptor signaling, SHP-1, cancer immunotherapy, CAR-T therapy, viral infections, HIV, COVID-19, tuberculosis, immune tolerance, Mayo Clinic

The study, led by Qiushuang Wu in the laboratory of Sohail Tavazoie, builds on earlier work linking arginine depletion to colon cancer. In 2023, Tavazoie’s team found that depriving colon cancer cells of arginine increased the number of mutations they accumulated. The new research suggests that arginine scarcity may have a second, potentially complementary effect: it can weaken immune surveillance by interfering with the cellular machinery responsible for producing MHC-I proteins.

MHC-I molecules are displayed on the surface of nearly every nucleated cell in the body. They bind short protein fragments generated inside cells and present them to cytotoxic T cells. When these fragments originate from viral proteins or altered cancer proteins, T cells can recognize the cells as dangerous and initiate their destruction. A reduction in MHC-I expression can therefore provide infected or malignant cells with a form of immune concealment, allowing them to evade detection.

The researchers focused on an unusual feature of MHC-I biology. The protein is encoded by genes whose messenger RNA contains a high number of codons specifying arginine. Codons are three-nucleotide sequences that direct ribosomes to insert particular amino acids into a growing protein chain. Although several codons can encode the same amino acid, MHC-I transcripts are particularly dependent on arginine-rich instructions. This dependence appears to make their translation unusually sensitive to fluctuations in the cellular supply of arginine.

Using cultured cells, Wu and colleagues measured changes in protein production under arginine-restricted conditions. They identified 414 proteins whose levels fell abnormally when arginine was scarce. Many were connected to processes already known to depend on arginine, including metabolism and signaling. The most consequential finding, however, involved three HLA genes that encode components of MHC-I. Their expression and the amount of MHC-I protein produced from them declined sharply during arginine deprivation.

Additional experiments indicated that the problem was not simply a failure to transcribe the genes into messenger RNA. Instead, ribosomes stalled while translating MHC-I messages. When a ribosome reaches an arginine codon, it normally receives an arginine-loaded transfer RNA molecule and continues building the protein. Under depleted conditions, the supply of these charged transfer RNAs falls. Ribosomes then pause at arginine-rich sections of the message, slowing or aborting production of the completed MHC-I protein. The result is a reduced ability to present intracellular antigens to T cells.

This mechanism may help explain why arginine levels decline in several disease settings. The researchers found that arginine was the most depleted amino acid across the disease models they examined, including colon cancer, influenza and SARS-CoV-2 infection. Tumors and infected tissues can alter nutrient availability by consuming amino acids rapidly, reshaping local metabolism or triggering systemic changes in nutrient distribution. In addition, arginine levels naturally tend to decrease with age, a change that could contribute to weaker immune responses in older individuals.

The team next tested whether dietary arginine could influence disease outcomes in living animals. Mice fed an arginine-restricted diet developed more colon tumors, whereas animals receiving higher amounts of the amino acid developed fewer tumors. The researchers then studied mouse models of influenza and SARS-CoV-2 infection. Animals on arginine-rich diets experienced milder symptoms than mice receiving lower amounts. In the influenza experiments, administering arginine after infection also improved outcomes, suggesting that supplementation may retain activity even after disease has begun.

The findings raise the possibility that arginine availability could influence responses to both immunotherapy and viral infection, although the evidence remains preclinical. A moderate amount of supplemental arginine was sufficient in laboratory experiments to restore expression of genes involved in MHC-I production, according to the researchers. They propose that arginine supplementation could eventually be evaluated alongside cancer immunotherapies or as a supportive intervention for people at high risk from respiratory viruses. Human studies will be necessary to determine appropriate doses, safety and effectiveness, particularly because arginine metabolism is complex and may affect tumors, pathogens and immune cells in different ways.

The study also points to a broader principle in molecular biology: nutrients may regulate gene expression not only through classical signaling pathways, but also through the physical demands of protein synthesis. If a protein contains an unusually high proportion of codons for a particular amino acid, its production could be selectively reduced when that amino acid becomes limited. Tavazoie’s team is now investigating whether similar codon-dependent effects occur with other amino acids and proteins. For viral disease and cancer, the work offers a new explanation for how altered metabolism can weaken immune recognition—and a potential route for restoring it through nutritional intervention.

Subject of Research: Arginine-dependent MHC-I protein translation, cancer immunity and respiratory viral infection

Article Title: Dietary arginine drives codon-dependent MHC-I translation and improves immunity in colon tumorigenesis and respiratory viral infection

Article Publication Date: 30-Jul-2026

Web References: https://www.rockefeller.edu/news/33574-the-nutrient-that-cancer-cells-crave/ ; https://www.rockefeller.edu/our-scientists/heads-of-laboratories/973-sohail-tavazoie/ ; https://snfiru.rockefeller.edu/

References: Cell, DOI: 10.1016/j.cell.2026.07.020

Image Credits: Elizabeth and Vincent Meyer Laboratory of Systems Cancer Biology at The Rockefeller University

Keywords: Arginine, MHC-I, HLA genes, codon-dependent translation, cancer immunity, colon cancer, influenza, SARS-CoV-2, viral infection, immune evasion, nutritional immunology

In the intricate world of cellular biology, every cell’s nucleus harbors genomic DNA, while mitochondria contain their own distinct mitochondrial DNA. When DNA escapes these compartments, whether from cellular apoptosis or external sources such as viral infections, it initiates a response through a highly conserved molecular pathway. The proteins cGAS and STING play pivotal roles in recognizing extracellular DNA, triggering a cascade of immune responses that ultimately alert neighboring cells and mobilize a defense against potential pathogens and aberrant cellular behaviors.

A remarkable feature of this immune pathway is its duality; while it serves as a powerful defense mechanism against various threats, its dysregulation can have detrimental consequences. The downregulation of this pathway is closely associated with immune evasion in cancers and viral infections. Conversely, when the response is aberrantly upregulated, it can lead to autoimmune diseases, where the immune system attacks the body’s own tissues. This delicate balance illustrates the need for precise regulation and understanding of these molecular pathways in health and disease.

The introduction of a novel fluorescent biosensor by researchers aims to fill a critical gap in the ability to visualize the dynamics of these cellular processes in real-time. By engineering the interaction between activated STING and IRF3, the biosensor provides profound insights into how cells respond to cGAMP, a secondary messenger in this immune detection pathway. This innovative tool enhances our understanding of single-cell responses and population dynamics during various physiological and pathological scenarios, including infections and cellular stress responses.

With this approach, scientists have begun to explore the dynamics of immune responses to Herpes virus infections and the release of mitochondrial DNA upon apoptosis. Moreover, the study reveals that tumorigenesis is often complicated by chromosomal missegregation, which leads to the presence of genomic DNA outside the nucleus. However, intriguing findings suggest that missegregated chromosomes do not induce an immune response via the STING pathway, potentially due to the protective packaging of DNA with histones, which makes it unrecognizable as a threat by the immune system.

These insights carry significant implications for the field of cancer research and the development of therapeutic strategies targeting chromosomally unstable tumors. Many clinical trials have focused on exploiting STING as a therapeutic target to stimulate immune responses against malignancies; however, the new findings indicate that the effectiveness of this approach could be complicated by the inherent properties of genomic DNA and how it is presented to the immune system.

The ramifications of this study extend far beyond mere academic interest. It has laid the groundwork for developing potential therapeutic interventions that could harness the immune system’s power to combat cancer and infectious diseases. By offering a method to visualize innate immune responses in complex biological settings, researchers can now better understand how immune cells communicate and respond to threats, leading to more effective therapies derived from these insights.

The resources allocated to this research project were significant, backed by funding from the Ikerbasque Foundation, Boehringer Ingelheim Fonds, and the excellence program of Heidelberg University. This support underscores the importance of this work within the scientific community and its potential impacts on public health.

As this study circulates through academic and scientific communities, it is poised to inspire future research endeavors exploring the multifaceted interactions between the immune system and cellular health. Understanding how to modulate these immune pathways could lead to groundbreaking strategies in treating viral infections and cancers that have thus far eluded effective intervention.

In conclusion, the innovative application of a biosensor to illuminate the spatiotemporal dynamics of the STING pathway significantly enhances our understanding of innate immune responses. As researchers continue to explore these mechanisms, they draw closer to unlocking new strategies to leverage the immune system in the fight against diseases marked by aberrant DNA responses. This pioneering work heralds a new era in immunology, where the visualization of cellular processes can lead to tangible advancements in therapeutic interventions.

Subject of Research: Innate Immune Response and STING Pathway
Article Title: A novel biosensor for the spatiotemporal analysis of STING activation during innate immune responses to dsDNA
News Publication Date: 21-Feb-2025
Web References: http://dx.doi.org/10.1038/s44318-025-00370-y
References: Not available
Image Credits: Credit: Ikerbasque

Keywords: Innate immune response, STING pathway, cGAS, IRF3, biosensor, immunology, cancer research, viral infections, apoptosis, chromosomal stability, genomic DNA, immune modulation.

The Epstein-Barr virus is widely recognized, as it is estimated that around 90 to 95 percent of the adult population are carriers. While numerous individuals contract EBV during childhood with minimal or no symptoms, young adults may experience glandular fever. This latent phase of infection means the virus persists in the body without causing active disease, raising questions about its role in neurodegenerative disorders such as MS.

One of the standout findings of the study is the identification of the specific EBV protein EBNA1. The researchers demonstrated that antibodies generated against EBNA1 could mistakenly bind to GlialCAM, a protein found in the brain that ensures the proper functioning of neuronal support cells. This unintended immune response may be a crucial player in the autoimmune attack that characterizes multiple sclerosis, indicating that the immune system’s aggressive actions could be misdirected due to molecular mimicry.

Moreover, the research does not stop at uncovering the antibodies’ misdirected behavior, but it also explores the intersection of genetic predisposition and immune responses. The study reveals that individuals carrying the HLA-DRB1*15:01 genetic variant, commonly associated with an increased risk of developing MS, exhibit heightened risks when coupled with elevated antibody levels against EBNA1 and GlialCAM. This dual factor appears to amplify the susceptibility to MS, highlighting the complex interplay between genetics and immunological responses in disease onset.

Another significant aspect of the research is the investigation of additional proteins that share structural similarities with EBNA1. The study included assessments of antibodies aimed at other proteins like ANO2 and CRYAB, which have analogous traits to EBNA1. High levels of these antibodies were also found in MS patients, reinforcing the notion that a broader array of misdirected immune responses could be at play in the landscape of multiple sclerosis.

Elevated antibody levels against these proteins were noted in MS patients as compared to healthy controls, reinforcing the concept of an underlying immune dysregulation. The absence of protective alleles, such as HLA-A*02:01, further compounds the situation by increasing the risk when any of the antibodies against the aforementioned brain proteins are present. This nuanced understanding may pave the way for new therapeutic approaches targeting these specific immune interactions, aiming to regulate or redirect the immune response in MS patients.

In light of these findings, researchers at Karolinska Institutet are embarking on further investigations, aiming to examine blood samples collected prior to any clinical manifestation of MS. By determining when these antibodies first emerge, the researchers could potentially identify biomarkers that herald the onset of the disease. Early detection of MS is crucial for effective intervention, as it holds the promise of mitigating disease progression and refining therapeutic strategies.

Understanding the mechanistic nuances of how EBV interacts with the immune system offers a tantalizing glimpse into potential diagnostic avenues. If the antibodies discovered in this research are found to be present before the onset of MS symptoms, they could serve as critical biomarkers for pre-symptomatic detection, fundamentally changing how the disease is monitored and managed.

In the landscape of autoimmune diseases, the link between infections and subsequent immune dysfunction has been of increasing interest. Previous research has suggested that viral infections can serve as triggers for autoimmune dysregulation, a theory that finds new support in the context of EBV and MS. The current study not only reinforces this theory but also underscores the importance of investigating viral etiology in neurodegenerative diseases.

Furthermore, the study’s outcomes emphasize the pressing need for a paradigm shift in how we regard the initiation of MS. With roughly 90 percent of the global population being EBV carriers, understanding the factors that differentiate between healthy individuals and those progressing to autoimmune conditions could hold the key to prevention strategies.

The insights gleaned from this research hold significant implications for clinical practice; healthcare providers could leverage this information to screen at-risk populations more effectively and leverage personalized medicine approaches in MS treatment and intervention. Additionally, the collaborative efforts of renowned institutions demonstrate the power of interdisciplinary research in tackling complex health challenges that have long puzzled the scientific community.

Ultimately, the findings pave the way for future research initiatives aimed at disarming the autoimmune responses that plague MS patients. As the interaction between EBV, genetic susceptibility, and the autoimmune response is further elucidated, the potential for groundbreaking diagnostic and therapeutic tools emerges, promising to transform the trajectory of multiple sclerosis management.

Subject of Research: Human tissue samples related to multiple sclerosis and the association with Epstein-Barr virus antibodies.

Article Title: Antibody reactivity against EBNA1 and GlialCAM differentiates multiple sclerosis patients from healthy controls.

News Publication Date: March 10, 2025.

Web References: DOI link to article

References: Neda Sattarnezhad et al., PNAS (Proceedings of the National Academy of Sciences)

Image Credits: Not available.

Keywords: Multiple sclerosis, Epstein-Barr virus, antibodies, genetic risk factors, biomarkers, autoimmune disorders, neuroscience, immunology, viral infections, human brain, neurodegeneration, MS research.